drugset / Trial / NCT03961815
Open-label Extension Study of Brazikumab in Crohn's Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of Study D5271C00002 (Legacy #3150-303-008) is to permit participants in D5271C00001 (Legacy #3150-301-008) to receive open-label brazikumab in Study D5271C00002 (Legacy #3150-303-008). This will permit long-term observation of safety in these participants with brazikumab.
Timeline
- Start
- 2020-01-06
- Primary completion
- 2023-09-19
- Completion
- 2023-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brazikumab | Unknown | — | Intravenous |